Advantage Alpha Capital Partners LP Purchases 10,172 Shares of ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Advantage Alpha Capital Partners LP significantly increased its stake in ANI Pharmaceuticals by 37,674.1% during the first quarter, owning a total of 10,199 shares valued at around $683,000.
• Insider transactions revealed that Director Jeanne Thoma and COO Muthusamy Shanmugam sold substantial shares amounting to $26.26 million over the last three months, indicating a decrease in their ownership percentages.
• ANI Pharmaceuticals reported a strong EPS of $1.80 for the latest quarter, surpassing estimates, and achieved revenue growth of 53.2% year-over-year.

Advantage Alpha Capital Partners LP increased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 37,674.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,199 shares of the specialty pharmaceutical company's stock after purchasing an additional 10,172 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in ANI Pharmaceuticals were worth $683,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ANIP. Principal Financial Group Inc. boosted its stake in ANI Pharmaceuticals by 68.3% in the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock worth $10,565,000 after purchasing an additional 64,021 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of ANI Pharmaceuticals by 53.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock worth $599,000 after acquiring an additional 3,112 shares during the last quarter. Invesco Ltd. raised its position in shares of ANI Pharmaceuticals by 1.0% during the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock worth $13,361,000 after acquiring an additional 2,022 shares during the last quarter. GAMMA Investing LLC raised its position in shares of ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after acquiring an additional 881 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of ANI Pharmaceuticals by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock valued at $15,959,000 after acquiring an additional 2,220 shares during the period. Institutional investors and hedge funds own 76.05% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ANIP. HC Wainwright reissued a "buy" rating and set a $93.00 price objective (up previously from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Guggenheim reissued a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Finally, Zacks Research upgraded shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $84.75.

Insider Buying and Selling

In related news, SVP Chad Gassert sold 20,000 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $86.97, for a total value of $1,739,400.00. Following the completion of the transaction, the senior vice president owned 173,226 shares in the company, valued at $15,065,465.22. This trade represents a 10.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Stephen P. Carey sold 50,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $86.07, for a total value of $4,303,500.00. Following the transaction, the chief financial officer directly owned 180,863 shares of the company's stock, valued at approximately $15,566,878.41. This represents a 21.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 405,538 shares of company stock valued at $35,690,131 over the last three months. Insiders own 12.70% of the company's stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP traded up $0.37 during trading on Wednesday, reaching $92.26. 94,566 shares of the stock were exchanged, compared to its average volume of 372,559. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $92.65. The stock has a 50-day moving average price of $71.72 and a 200-day moving average price of $66.38. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The firm has a market cap of $2.00 billion, a PE ratio of -119.82 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same period in the prior year, the firm posted $1.02 EPS. The company's revenue for the quarter was up 53.2% on a year-over-year basis. Research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.